CLINICAL TRIALS PROFILE FOR RELUGOLIX
✉ Email this page to a colleague
All Clinical Trials for Relugolix
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02083185 ↗ | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | Completed | Millennium Pharmaceuticals, Inc. | Phase 2 | 2014-03-26 | The purpose of this study is to evaluate the efficacy of TAK 385 for achieving and maintaining testosterone suppression (<50 ng/dL). |
| NCT02655224 ↗ | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | Completed | Takeda | Phase 3 | 2016-03-26 | The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids. |
| NCT02655237 ↗ | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | Completed | Takeda | Phase 3 | 2016-03-05 | The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously [SC]/time) in patients with uterine fibroids. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Relugolix
Condition Name
Clinical Trial Locations for Relugolix
Trials by Country
Clinical Trial Progress for Relugolix
Clinical Trial Phase
Clinical Trial Sponsors for Relugolix
Sponsor Name
